Rhelion subsidiary Filament Health to deliver oral comments at FDA hearing
Rhelion Life Sciences says its wholly owned subsidiary, Filament Health, will deliver oral comments at an FDA public hearing on potential future therapeutic use of psychedelic drugs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.